NIH picks PharmAthene for vaccine

PharmAthene Inc., an Annapolis-based biodefense company, has been awarded a federal contract to develop an anthrax vaccine, worth a possible $28.1 million, the company announced this week. The contract came from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. PharmAthene is to work on a next generation anthrax vaccine based on the company’s proprietary rPA vaccine. PharmAthene believes it can develop a vaccine that has improved long-term stability compared to existing liquid anthrax vaccines.